New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:43 EDTAERIAerie Pharmaceuticals price target raised to $36 from $27 at RBC Capital
RBC Capital believes that Phase IIb results for Aerie's glaucoma treatment, Roclatan, lower the risks faced by the company. The firm says that the data would be good enough to support approval of the drug if the trial was a Phase III study. It keeps an Outperform rating on the shares.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
10:00 EDTAERIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
March 24, 2015
16:06 EDTAERIAerie Pharmaceuticals initiated with a Buy at Brean Capital
Subscribe for More Information
06:02 EDTAERIAerie Pharmaceuticals completes enrollment for Phase 3 trial of Rhopressa
Aerie Pharmaceuticals announced the completion of enrollment in the Company’s second Phase 3 registration trial of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure,or IOP, in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use